Mechanism of growth inhibition of prostate cancer xenografts by valproic acid

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Sidana, Abhinav ^a   Wang, Muwen ^a   Shabbeer, Shabana ^b   Chowdhury, Wasim H ^a   Netto, George ^a   Lupold, Shawn E ^a   Carducci, Michael ^b   Rodriguez, Ronald ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D1; CYTOKERATIN 18; DRINKING WATER; PROTEIN P21; PROTEIN P27; VALPROIC ACID; HISTONE DEACETYLASE INHIBITOR; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG PELLET; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT DURATION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE CHECKPOINT; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOPHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; VALPROIC ACID;

EID: 84871824758     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/180363     Document Type: Article

References (38)

1. Rephaeli A., Blank-Porat D., Tarasenko N., Entin-Meer M., Levovich I., Cutts S. M., Phillips D. R., Malik Z., Nudelman A., In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. International Journal of Cancer 2005 116 2 226 235 2-s2.0-22044435505 10.1002/ijc.21030 (Pubitemid 40967259)
2. Konstantinopoulos P. A., Karamouzis M. V., Papavassiliou A. G., Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond. Expert Opinion on Investigational Drugs 2007 16 5 569 571 2-s2.0-34248190854 10.1517/13543784.16.5.569 (Pubitemid 46723267)
3. Dokmanovic M., Marks P. A., Prospects: histone deacetylase inhibitors. Journal of Cellular Biochemistry 2005 96 2 293 304 2-s2.0-26444439216 10.1002/jcb.20532 (Pubitemid 41437862)
4. Sowa Y., Orita T., Hiranabe-Minamikawa S., Nakano K., Mizuno T., Nomura H., Sakai T., Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Annals of the New York Academy of Sciences 1999 886 195 199 2-s2.0-0033427145 (Pubitemid 30042437)
5. Blagosklonny M. V., Are p27 and p21 cytoplasmic oncoproteins? Cell Cycle (Georgetown, Tex.) 2002 1 6 391 393 2-s2.0-0042197268
6. Göttlicher M., Minucci S., Zhu P., Krämer O. H., Schimpf A., Giavara S., Sleeman J. P., Lo Coco F., Nervi C., Pelicci P. G., Heinzel T., Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. The EMBO Journal 2002 20 24 6969 6978 2-s2.0-18244383806 10.1093/emboj/20.24.6969 (Pubitemid 34062289)
7. Xia Q., Sung J., Chowdhury W., Chen C. L., Höti N., Shabbeer S., Carducci M., Rodriguez R., Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Research 2006 66 14 7237 7244 2-s2.0-33746883106 10.1158/0008-5472.CAN-05-0487 (Pubitemid 44197704)
8. Shabbeer S., Kortenhorst M. S. Q., Kachhap S., Galloway N., Rodriguez R., Carducci M. A., Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 2007 67 10 1099 1110 2-s2.0-34250872780 10.1002/pros.20587 (Pubitemid 46983339)
9. Chen C.-L., Sung J., Cohen M., Chowdhury W. H., Sachs M. D., Li Y., Lakshmanan Y., Yung B. Y. M., Lupold S. E., Rodriguez R., Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. Journal of Pharmacology and Experimental Therapeutics 2006 319 2 533 542 2-s2.0-33751191671 10.1124/jpet.106.106658
10. Turnbull D. M., Rawlins M. D., Weightman D., Chadwick D. W., Plasma concentrations of sodium valproate: their clinical value. Annals of Neurology 1983 14 1 38 42 2-s2.0-0020609239 (Pubitemid 13070069)
11. Zha S., Gage W. R., Sauvageot J., Saria E. A., Putzi M. J., Ewing C. M., Faith D. A., Nelson W. G., De Marzo A. M., Isaacs W. B., Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Research 2001 61 24 8617 8623 2-s2.0-0035893745 (Pubitemid 34013865)
12. Manley S., Mucci N. R., De Marzo A. M., Rubin M. A., Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome the prostate specialized program of research excellence model. American Journal of Pathology 2001 159 3 837 843 2-s2.0-0034847476 (Pubitemid 32847175)
13. Faith D. A., Isaacs W. B., Morgan J. D., Fedor H. L., Hicks J. L., Mangold L. A., Walsh P. C., Partin A. W., Platz E. A., Luo J., De Marzo A. M., Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 2004 61 3 215 227 2-s2.0-5344230113 10.1002/pros.20095 (Pubitemid 39350443)
14. De Marzo A. M., Knudsen B., Chan-Tack K., Epstein J. I., E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999 53 4 707 713 2-s2.0-0033119141 10.1016/S0090-4295(98)00577-9 (Pubitemid 29163034)
15. Marshall C., How do small GTPase signal transduction pathways regulate cell cycle entry? Current Opinion in Cell Biology 1999 11 6 732 736 2-s2.0-0032750043 10.1016/S0955-0674(99)00044-7
16. Alt J. R., Gladden A. B., Diehl J. A., p21Cip1 promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. The Journal of Biological Chemistry 2002 277 10 8517 8523 2-s2.0-0037040984 10.1074/jbc.M108867200 (Pubitemid 34968314)
17. Schlage W. K., Bülles H., Friedrichs D., Kuhn M., Teredesai A., Terpstra P. M., Cytokeratin expression patterns in the rat respiratory tract as markers of epithelial differentiation in inhalation toxicology. II. Changes in cytokeratin expression patterns following 8-day exposure to room-aged cigarette sidestream smoke. Toxicologic Pathology 1998 26 3 344 360 2-s2.0-2642629705 (Pubitemid 28224273)
18. Wang Y., Hayward S. W., Cao M., Thayer K. A., Cunha G. R., Cell differentiation lineage in the prostate. Differentiation 2001 68 4-5 270 279 2-s2.0-0035495974 (Pubitemid 33754999)
19. Schaller G., Fuchs I., Pritze W., Ebert A., Herbst H., Pantel K., Weitzel H., Lengyel E., Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clinical Cancer Research 1996 2 11 1879 1885 2-s2.0-0029805461 (Pubitemid 26384156)
20. Santos A. F., Huang H., Tindall D. J., The androgen receptor: a potential target for therapy of prostate cancer. Steroids 2004 69 2 79 85 2-s2.0-1542315629 10.1016/j.steroids.2003.10.005 (Pubitemid 38315080)
21. Ananthanarayanan V., Deaton R. J., Yang X. J., Pins M. R., Gann P. H., Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 2006 6, article 73 2-s2.0-33847168993 10.1186/1471-2407-6-73 (Pubitemid 46277068)
22. Fina L., Molgaard H. V., Robertson D., Bradley N. J., Monaghan P., Delia D., Sutherland D. R., Baker M. A., Greaves M. F., Expression of the CD34 gene in vascular endothelial cells. Blood 1990 75 12 2417 2426 2-s2.0-0025329430 (Pubitemid 20202322)
23. Yildiz E., Ayan S., Goze F., Gokce G., Gultekin E. Y., Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma. BJU International 2008 101 6 758 764 2-s2.0-39449110749 10.1111/j.1464-410X.2007.07318.x (Pubitemid 351270001)
24. Liu T., Kuljaca S., Tee A., Marshall G. M., Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treatment Reviews 2006 32 3 157 165 2-s2.0-33645950778 10.1016/j.ctrv.2005.12.006
25. Rosato R. R., Grant S., Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opinion on Therapeutic Targets 2005 9 4 809 824 2-s2.0-23644434852 10.1517/14728222.9.4.809 (Pubitemid 41131680)
26. Sambucetti L. C., Fischer D. D., Zabludoff S., Kwon P. O., Chamberlin H., Trogani N., Xu H., Cohen D., Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. The Journal of Biological Chemistry 1999 274 49 34940 34947 2-s2.0-0033520944 10.1074/jbc.274.49.34940 (Pubitemid 129509542)
27. Iwata S., Saito T., Ito Y., Kamakura M., Gotoh K., Kawada J.-I., Nishiyama Y., Kimura H., Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Cancer Science 2012 103 2 375 381 2-s2.0-84856504569 10.1111/j.1349-7006.2011.02127.x
28. Kuendgen A., Gattermann N., Valproic acid for the treatment of myeloid malignancies. Cancer 2007 110 5 943 954 2-s2.0-34548176264 10.1002/cncr.22891 (Pubitemid 47312858)
29. Ocker M., Schneider-Stock R., Histone deacetylase inhibitors: signalling towards p21cip1/waf1. International Journal of Biochemistry and Cell Biology 2007 39 7-8 1367 1374 2-s2.0-34250171437 10.1016/j.biocel.2007.03.001 (Pubitemid 47031035)
30. Li W., Sanki A., Karim R. Z., Thompson J. F., Lee C. S., Zhuang L., McCarthy S. W., Scolyer R. A., The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006 38 4 287 301 2-s2.0-33747599365 10.1080/00313020600817951 (Pubitemid 44266625)
31. Bartek J., Bartkova J., Lukas J., The retinoblastoma protein pathway and the restriction point. Current Opinion in Cell Biology 1996 8 6 805 814 2-s2.0-0030561571 10.1016/S0955-0674(96)80081-0 (Pubitemid 26399940)
32. Parry D., Mahony D., Wills K., Lees E., Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Molecular and Cellular Biology 1999 19 3 1775 1783 2-s2.0-0032980425 (Pubitemid 29098236)
33. Willipinski-Stapelfeldt B., Riethdorf S., Assmann V., Woelfle U., Rau T., Sauter G., Heukeshoven J., Pantel K., Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clinical Cancer Research 2005 11 22 8006 8014 2-s2.0-28144440871 10.1158/1078-0432.CCR-05-0632 (Pubitemid 41698741)
34. Marks P. A., Richon V. M., Rifkind R. A., Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. Journal of the National Cancer Institute 2000 92 15 1210 1216 2-s2.0-0034596309 (Pubitemid 30627729)
35. Isaacs J. T., Isaacs W. B., Androgen receptor outwits prostate cancer drugs. Nature Medicine 2004 10 1 26 27 2-s2.0-1842612442 10.1038/nm0104-26 (Pubitemid 38524693)
36. Ali I. U., Senger D. R., Smith L. E. H., Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials. Urology 2001 57 4 143 147 2-s2.0-0034969921 10.1016/S0090-4295(00)00961-4 (Pubitemid 32532405)
37. Schlingemann R. O., Rietveld F. J. R., De Waal R. M. W., Bradley N. J., Skene A. I., Davies A. J. S., Greaves M. F., Denekamp J., Ruiter D. J., Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Laboratory Investigation 1990 62 6 690 696 2-s2.0-0025376269 (Pubitemid 20213686)
38. Sabo E., Boltenko A., Sova Y., Stein A., Kleinhaus S., Resnick M. B., Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clinical Cancer Research 2001 7 3 533 537 2-s2.0-0034900897 (Pubitemid 32707975)